mitomycin has been researched along with camptothecin in 170 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.59) | 18.7374 |
| 1990's | 25 (14.71) | 18.2507 |
| 2000's | 89 (52.35) | 29.6817 |
| 2010's | 52 (30.59) | 24.3611 |
| 2020's | 3 (1.76) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, P; Kumar, A; Qazi, GN; Saxena, AK; Sethi, VK; Shah, BA; Sharma, M; Singh, J; Taneja, SC | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ashraf, M; Bhushan, S; Chashoo, G; Kamal, A; Kashi Reddy, M; Kaur, T; Mondhe, DM; Naseer Ahmed Khan, M; Saxena, A; Saxena, AK; Sehar, I; Sharma, PR; Srikanth, YV; Sultana, F; Suri, N; Wani, ZA | 1 |
| Hamid, A; Kumar, A; Saxena, AK; Sethi, VK; Shah, BA; Singh, J; Singh, S; Singh, SK; Taneja, SC | 1 |
| Chashoo, G; Chinthakindi, PK; Hamid, A; Koul, S; Majeed, R; Reddy, MV; Sangwan, PL; Saxena, AK | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Bhushan, S; Murthy, YL; Nagendra Sastry, Y; Pathania, AS; Suhasini, KP | 1 |
| Alam, MS; Arvinda, S; Chashoo, G; Gupta, BD; Hyder, I; Khazir, J; Kumar, HM; Mahajan, A; Reddy, DM; Sawant, SD; Saxena, AK; Shafi, S; Singh, PP | 1 |
| Chinthakindi, PK; Dangroo, NA; Hamid, A; Khan, I; Koul, S; Majeed, R; Sangwan, PL; Saxena, AK; Sharma, PR; Thota, N | 1 |
| Arora, S; Chaudhary, A; Ishar, MP; Saxena, AK; Sharma, V | 1 |
| Alam, MS; Chasoo, G; Gayatri, JL; Hyder, I; Khazir, J; Mahajan, A; Nalla, N; Prasad Yandrati, L; Qazi, GN; Sampath Kumar, HM; Saxena, AK | 1 |
| Arora, S; Chaudhry, A; Gupta, V; Ishar, MPS; Kumar, R; Sharma, V; Sood, A | 1 |
| Arora, R; Arora, S; Chashoo, G; Chaudhry, A; Ishar, MP; Saxena, AK; Sharma, V | 1 |
| Przybylski, P; Łowicki, D | 1 |
| Kondo, K; Kume, T; Oishi, M; Shiraishi, T; Tsuneizumi, K; Watanabe, T | 1 |
| Cimoli, G; Conte, P; Conzi, G; Noviello, E; Orengo, G; Pagnan, G; Parodi, S; Russo, P; Schenone, F; Venturini, M | 1 |
| Erlichman, C | 1 |
| Furuta, T; Yokokura, T | 1 |
| Caldecott, K; Jeggo, P | 1 |
| Covey, JM; Kao-Shan, CS; Kerrigan, D; Pommier, Y; Whang-Peng, J | 1 |
| Fujita, F; Fujita, M; Sakamoto, Y | 1 |
| Grompe, M; Jakobs, PM; Moses, RE; Neeley, TL; Saito, H | 1 |
| Arai, H; Fujii, N; Kasai, M; Nakano, H; Saito, H | 1 |
| Funayama, Y; Kubota, N; Miyahara, Y; Nishio, K; Ogasawara, H; Ohira, T; Ohmori, T; Podack, ER; Takahashi, M; Takeda, Y | 1 |
| Emoto, Y; Kharbanda, S; Kisaki, H; Kufe, D; Manome, Y | 1 |
| Hasumi, K; Shimizu, Y; Umezawa, S | 3 |
| Creus, A; Marcos, R; Ribas, G; Xamena, N | 1 |
| Cowan, KH; Fukuda, M; Ikeda, K; Kohno, S; Matsuo, I; Nakano, R; Narasaki, F; Oka, M; Soda, H; Takatani, H; Terashi, K; Tomonaga, M | 1 |
| Shimizu, Y | 1 |
| Fujimura, M; Fushiki, H; Hidaka, T; Hori, S; Izumi, R; Yamakawa, Y | 1 |
| Masuda, N | 1 |
| Saijo, N | 1 |
| Sakata, Y; Tsushima, K | 1 |
| André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M | 1 |
| Corey, EJ; Martinez, EJ; Owa, T; Schreiber, SL | 1 |
| Eckardt-Schupp, F; Friedl, AA; Jaspers, NG; Klein, B; Kraakman-van der Zwet, M; Lohman, PH; Midro, AT; Overkamp, WJ; Verhaegh, GW; Zdzienicka, MZ | 1 |
| Gobert, C; Larsen, AK; Skladanowski, A | 1 |
| Johnson, MA; Jones, NJ | 1 |
| Hotta, T; Ishimoto, K; Iwahashi, M; Matsuda, K; Tanaka, H; Tani, M; Tanimura, H; Tsunoda, T; Yamaue, H | 1 |
| Arimoto, J; Bessho, T; Furukawa, T; Hirai, I; Maebeya, S; Matsuyama, K; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yano, T; Yoshimasu, T | 1 |
| Barret, JM; Etiévant, C; Hill, BT | 1 |
| Bryant, PE; Johnson, MA; Jones, NJ | 1 |
| Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Nakashima, H; Okamura, T; Toh, Y | 1 |
| Sandler, A | 1 |
| Cunningham, D; Sumpter, K | 1 |
| Ogita, S; Tanaka, T; Umesaki, N | 1 |
| Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC | 1 |
| Cunningham, D; Waters, J | 1 |
| Flieger, D; Hoff, AS; Sauerbruch, T; Schmidt-Wolf, IG | 1 |
| Avallone, A; Biglietto, M; Casaretti, R; Comella, G; Comella, P; De Cataldis, G; De Lucia, L; Di Lullo, L; Maiorino, L; Rivellini, F | 1 |
| Delitheos, A; Miligkos, V; Papamichael, K; Tiligada, E; Ypsilantis, E | 1 |
| Adam, R; Antoine, EC; Bassot, V; Benhammonda, A; Bismuth, H; Castaing, D; Gil-Delgado, MA; Grapin, JP; Guinet, F; Khayat, D | 1 |
| Sakata, Y | 1 |
| Budd, RC; Ito, M; Kataoka, T; Nagai, K; Tschopp, J | 1 |
| Chin, K; Goto, M; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yamao, T | 1 |
| Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J | 1 |
| Fujimura, M; Fushiki, H; Izumi, R; Nakashima, A; Saito, S; Yuuki, H | 1 |
| Ciftci, K; Su, J | 1 |
| Akeshima, R; Iba, T; Itamochi, H; Kamazawa, S; Kanamori, Y; Kigawa, J; Sultana, H; Terakawa, N | 1 |
| Kolesar, JM; Villalona-Calero, MA | 1 |
| Furuichi, Y; Goto, M; Hayashi, M; Honma, M; Sakamoto, H; Satoh, T; Sofuni, T; Sugimoto, M; Tadokoro, S; Tanabe, H | 1 |
| Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P | 1 |
| Ansell, W; Nystrom, M; Oliver, RT; Shamash, J; Steele, JP; Wilson, P | 1 |
| Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y | 1 |
| Shapiro, CL; Xu, Y | 1 |
| Ishihara, A; Nagao, K; Tanaka, H; Toyoda, N; Umekawa, T | 1 |
| Barber, LJ; Carr, AM; Hartley, JA; Lambert, S; Mason, SJ; McHugh, PJ; Pearce, JA | 1 |
| Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K | 1 |
| Hiwasa, T; Iwadate, Y; Noda, A; Sakaida, T; Takiguchi, M; Uehara, M; Yamaji, S; Yamaura, A | 1 |
| Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E | 1 |
| Hasuike, Y; Kashiwazaki, M; Mishima, H; Nishisyo, I; Takeda, Y; Tsujinaka, T | 1 |
| Bolderson, E; Helleday, T; Meuth, M; Mohindra, A; Stone, J; Wells, M | 1 |
| Benedicic, Ch; Petru, E; Pickel, H; Seewann, A | 1 |
| Akaike, T; Fang, J; Greish, K; Maeda, H; Sawa, T | 1 |
| Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Tsuzuki, T | 1 |
| Limper, AH | 1 |
| Du, GZ; Gao, JF; Li, CS; Ou, WL; Wang, J; Yang, B; Zhang, BC; Zhang, XH; Zhu, YZ | 1 |
| Fanning, E; Gu, J; Liu, H; Podust, VN; Reynolds, AB; Xia, X; Yan, P | 1 |
| Cejka, P; Jiricny, J; Papouli, E | 1 |
| Fenske, A; Hribaschek, A; Krüger, S; Lippert, H; Meyer, F; Pross, M; Ridwelski, K | 1 |
| Fujii, T; Fushiki, H; Hasegawa, K; Izumi, R; Nishida, M; Nishimura, R; Takizawa, K; Tanaka, T; Umesaki, N; Yamamoto, K | 1 |
| Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Kubo, Y; Kurita, A; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tsuzuki, T; Tubouchi, E | 1 |
| Terauchi, F | 1 |
| Iishi, H; Narahara, H; Sugimoto, N; Tatsuta, M | 1 |
| Bonetto, E; Di Carlo, V; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Ronzoni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Aoki, Y; Fujita, K; Kurata, H; Tanaka, K; Watanabe, M | 1 |
| Dhaliwal, K; Evans, MT; Fennell, DA; Gower, N; Parmar, A; Rudd, R; Shamash, J; Sheaff, MT; Steele, J; Sylvester, R | 1 |
| Bissler, JJ; Dixon, K; Lu, L; Robison, JG | 1 |
| Ansell, W; Oliver, T; Powles, T; Shamash, J; Wilson, P | 1 |
| Dan, S; Fukui, Y; Nakamura, T; Nakatsu, N; Yamazaki, K; Yamori, T; Yoshida, Y | 1 |
| Ji, J; Ji, YB; Lin, YZ; Liu, BY; Yuan, F; Zhang, J; Zhu, ZG | 1 |
| Amikura, T; Aoki, Y; Fujita, K; Nishino, K; Obata, H; Sekine, M; Tanaka, K; Yahata, T | 1 |
| Hirose, K; Nishimura, M; Sawada, T | 1 |
| Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N | 1 |
| Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K | 1 |
| Battaglia, C; Colucci, G; Di Bisceglie, M; Gebbia, N; Gebbia, V; Giuliani, F; Maiello, E; Molica, S; Vinciarelli, G | 1 |
| Kokawa, K; Tanaka, T; Umesaki, N | 1 |
| Fujita, J; Hoshimoto, S; Kato, R; Kato, T; Morise, Z; Sugioka, A | 1 |
| Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y | 1 |
| Bai, T; Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Matsui, H; Matsuzaki, Y; Miyazaki, K; Nakahara, A; Sato, D; Shibahara, T; Suzuki, H; Uchida, K; Yanaka, A | 1 |
| Ishihara, A; Kihira, T; Nomura, Y; Tanaka, H | 1 |
| Kaneko, H; Koshino, H; Kurihara, A; Otsuka, Y; Takita, W; Tamura, A; Teramoto, T; Tsuchiya, M; Watanabe, M; Yamazaki, K | 1 |
| Evans, MT; Fennell, DA; Rudd, RM; Shamash, J; Sheaff, MT; Stebbing, J; Steele, JP; Wells, P | 1 |
| Aphinives, P; Bhudhisawasdi, V; Sae-seow, O; Uttaravichien, T | 1 |
| Becherel, OJ; Chen, P; de Murcia, G; de Murcia, JM; Epe, B; Fusser, M; Grattan-Smith, P; Gueven, N; Haince, JF; Howe, O; Lavin, MF; McGowan, CH; Mothersill, C; Ouellet, ME; Parton, R; Poirier, GG; Waterhouse, N | 1 |
| Glimelius, B; Graf, W; Grundmark, B; Larsson, R; Mahteme, H; Nygren, P; Påhlman, L; Tholander, B; von Heideman, A | 1 |
| Fennell, DA; Rudd, RM; Shamash, J; Sheaff, MT; Slater, SE; Stebbing, J; Steele, JP; Wells, P | 1 |
| Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N | 1 |
| Cao, Y; Chen, F; Payne, R; See, WA; Zhang, G | 1 |
| Bonnet, S; Boulet, T; Di Pietrantonio, D; Elias, D; Goere, D; Honore, C; Kohneh-Shahri, N; Raynard, B | 1 |
| Allen, J; Kolesar, J; Mrozek, E; Shapiro, CL; Villalona-Calero, M; Young, D | 1 |
| Healey-Bird, BR; Kemeny, NE; Power, DG | 1 |
| Gautier, J; Hoatlin, ME; Stone, S; Wang, LC | 1 |
| Drengler, R; Duan, W; Kolesar, JM; Kuhn, J; Otterson, G; Schaaf, LJ; Shapiro, C; Villalona-Calero, MA; Xu, Y | 1 |
| al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW | 1 |
| Balzer, JO; Eichler, K; Gruber, T; Hammerstingl, R; Vogl, TJ; Zangos, S | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Ahn, KD; Cho, YB; Choi, SH; Chun, HK; Kim, HC; Lee, JM; Lee, WY; Shin, HJ; Song, SY; Yun, SH | 1 |
| Asanuma, F; Atsuda, K; Hiraku, O; Inoue, G; Morimoto, Y; Sasaki, K; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoshizawa, J | 1 |
| Drolet, P; Dubé, P; Leblanc, G; Leclerc, YE; Mitchell, A; Sideris, L | 1 |
| Arce-Lara, C; Bekaii-Saab, T; Cataland, S; Kraut, E; Ntukidem, N; Otterson, GA | 1 |
| Airoldi, G; Bassi, MT; Bonato, S; Bondioni, S; Bresolin, N; Cantoni, O; Clementi, E; Crimella, C; De Palma, C; Falcone, S; Grazia D'Angelo, M; Guidarelli, A; Panzeri, C; Tonelli, A; Vantaggiato, C | 1 |
| Akashi, R; Kanda, K; Kiyozumi, T; Koba, I; Miyamoto, H; Sagara, K; Yamanouchi, T; Yoshida, M; Zinnouchi, K | 1 |
| Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK | 1 |
| Chen, LH; Guan, J; Li, QS; Sun, HW; Wei, CJ; Zheng, XK | 1 |
| Darroudi, F; de Groot, J; de Winter, JP; Godthelp, BC; Joenje, H; Oostra, AB; Scheper, RJ; Steltenpool, J; van der Lelij, P; van Gosliga, D; van Zon, W; Waisfisz, Q; Wolthuis, RM | 1 |
| Chatelut, E; Ferron, G; Gadiou, M; Gladieff, L; Halilou, MC; Hennebelle, I; Herin, F; Simon, L | 1 |
| Arai, T; Hirai, H; Imagaki, K; Iwasawa, Y; Kobayashi, M; Kotani, H; Mizuarai, S; Nishibata, T; Ohtani, J; Okada, M; Sakai, N; Sakai, T; Yoshizumi, T | 1 |
| Abbas, A; Bekaii-Saab, T; Burak, W; Lustberg, MB; Lustberg, ME; McCracken-Bussa, B; Otterson, G; Villalona-Calero, MA; Young, D | 1 |
| Bushell, M; Chew, EH; Chua, YL; Gao, J; Hagen, T; Lou, JJ | 1 |
| Chiba, Y; Fukuoka, M; Hida, T; Imamura, F; Iwamoto, Y; Katakami, N; Kawahara, M; Kudo, S; Nakagawa, K; Nishimura, Y; Saka, H; Satouchi, M; Sawa, T; Semba, H; Seto, T; Takeda, K; Tsujino, K; Uejima, H; Yamamoto, N; Yokota, S | 1 |
| Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW | 1 |
| Chessa, L; De Amicis, A; Delia, D; Fanciulli, M; Ferrari, F; Piane, M | 1 |
| Bettecken, T; de Winter, JP; Eirich, K; Hain, K; Hilhorst-Hofstee, Y; Jaspers, NG; Joenje, H; Korthof, ET; Nieuwint, AW; Oostra, AB; Rooimans, MA; Rouse, J; Schindler, D; Schuster, B; Steltenpool, J; Stoepker, C | 1 |
| Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Mohamed, F; Passot, G; Steghens, A; Tod, M | 1 |
| Arai, Y; Boku, N; Denda, T; Fujii, H; Hamaguchi, T; Hyodo, I; Iwase, H; Koizumi, W; Ohtsu, A; Saito, H; Shirao, K; Takiuchi, H; Yoshida, M | 1 |
| Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W | 1 |
| Bhattacharyya, M; Mutsvangwa, K; Oliver, T; Powles, T; Shamash, J; Wilson, P | 1 |
| Peeters, M; Price, T | 1 |
| Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E | 1 |
| Blum, HE; Breidert, M; Euringer, W; Fischer, R; Harder, J; Kuhlmann, JB; Spangenberg, HC | 1 |
| Boisvert, RA; Cavallo, F; Esashi, F; Howlett, NG; Jasin, M; Mauro, M; Rego, MA | 1 |
| Antonelli, G; Blandino, R; Calì, S; Ferraù, F; Malaponte, E; Panebianco, V; Vitale, FV | 1 |
| Auerbach, AD; Kim, Y; Lach, FP; Smogorzewska, A; Spitz, GS; Veturi, U | 1 |
| Al-Kasspooles, MF; Decedue, CJ; Henry, D; Howell, J; Niu, F; Roby, KF; Williamson, SK | 1 |
| Hu, J; Li, X; Liu, Z; Lu, Z; Sun, Y; Wang, J; Wang, Q; Yan, L | 1 |
| Cassidy, J; Hochster, H | 1 |
| Brown, GW; Giaever, G; Lee, AY; Nislow, C; Torres, NP | 1 |
| Korovina, IaV; Nasyrov, AR; Pirtskhalava, TL | 1 |
| Ando, T; Fujinami, H; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, T; Mihara, H; Minemura, M; Nishikawa, J; Note, M; Ogawa, K; Sugiyama, T; Terada, M; Ueda, A; Yabushita, K; Yoshita, H | 1 |
| Cao, R; Chen, X; Geng, M; Li, P; Wang, L | 1 |
| Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Passot, G; Roux, AS; Vaudoyer, D | 1 |
| Abe, H; Ishibashi, H; Ishigaki, K; Itobayashi, E; Iwai, Y; Katagiri, T; Komata, S; Kubota, M; Matsushima, T; Miyakawa, A; Nakamura, A; Sakaguchi, Y; Shimura, H; Shimura, K; Suzuki, Y; Takashina, A; Tamura, T | 1 |
| Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ | 1 |
| Iwai, S; Kametani, Y; Kuraoka, I | 1 |
| Hirano, S; Kuroda, A; Kuwatani, T; Kyogoku, N; Maki, T; Miyauchi, K; Shichinohe, T; Takeuchi, S; Tsuchikawa, T; Wada, M; Yamamura, Y | 1 |
| Kusakabe, T; Lee, JM; Mon, H; Shiotsuki, T; Sugahara, R | 1 |
| Andréasson, H; Bjersand, K; Graf, W; Larsson, R; Mahteme, H; Nygren, P; Sundström Poromaa, I | 1 |
| Adelman, CA; Borel, V; Boulton, SJ; Matsuzaki, K; Schindler, D | 1 |
| Allen, PJ; D'Angelica, MI; DeMatteo, RP; Do, RK; Fong, Y; Gönen, M; Groot Koerkamp, B; Jarnagin, WR; Kemeny, NE; Kingham, TP; Klimstra, DS; Konstantinidis, IT | 1 |
| Bakrin, N; Bonnefoy, I; Cotte, E; Glehen, O; Kepenekian, V; Kim, BJ; Passot, G; Vaudoyer, D | 1 |
| Azad, NS; De Jesus-Acosta, A; Donehower, RC; Fine, RL; Goggins, M; Jaffee, EM; Johnson, BA; Laheru, DA; Le, DT; Myzak, MC; Oberstein, PE; Yarchoan, M; Zheng, L | 1 |
| Albrecht, MH; Gruber-Rouh, T; Hammerstingl, R; Lahrsow, M; Thompson, ZM; Vogl, TJ | 1 |
| Gu, S; Jin, L; Ma, J; Ni, X; Pan, Q; Wang, J; Xu, M; Zhen, N; Zhu, J | 1 |
| Boroda, AV; Kipryushina, YO; Odintsova, NA | 1 |
| Gao, Y; Hua, Y; Mao, S; Shi, R; Song, S; Tian, B; Wang, L; Wang, Y; Xiao, Y; Xu, H; Xu, X; Zhao, Y | 1 |
| Aalbers, AGJ; Bakkers, C; Boerma, D; Brandt-Kerkhof, ARM; Bremers, AJA; Buffart, TE; Burger, JWA; Creemers, GM; de Groot, DJA; de Hingh, IHJT; de Reuver, PR; Dijkgraaf, MGW; Fijneman, RJA; Hemmer, PHJ; Kok, NFM; Koopman, M; Kranenburg, O; Kruijff, S; Kusters, M; Lahaye, MJ; Los, M; Madsen, EVE; Nederend, J; Nienhuijs, SW; Punt, CJA; Rovers, KP; Snaebjornsson, P; Tanis, PJ; Thijs, AMJ; Tuynman, JB; van 't Erve, I; van Grevenstein, WMU; van Meerten, E; Verheul, HMW; Versteeg, KS; Wiezer, MJ; Witkamp, AJ | 1 |
23 review(s) available for mitomycin and camptothecin
| Article | Year |
|---|---|
Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
Topics: Bridged Bicyclo Compounds; Nitrogen | 2022 |
Novel chemotherapeutic agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Mitomycin; Mitomycins; Paclitaxel; Pyrazoles; Quinazolines; Thiophenes; Topotecan | 1991 |
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Transitional Cell; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1997 |
[Combination chemotherapy in the treatment of inoperable non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Mitomycin; Paclitaxel; Survival Rate; Vinblastine; Vindesine; Vinorelbine | 1997 |
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Methotrexate; Mitomycin; Neoplastic Cells, Circulating; Peritoneal Neoplasms; Stomach Neoplasms | 1998 |
[Irinotecan in combination for colon cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Europe; Fluorouracil; Irinotecan; Japan; Leucovorin; Mitomycin; Neoplasm Metastasis; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors; Treatment Outcome; United States | 1998 |
[State of the treatment for gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Mitomycin; Stomach Neoplasms | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Combination chemotherapy and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2000 |
The changing face of chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Thymidylate Synthase; Topoisomerase I Inhibitors | 2001 |
[Irinotecan (CPT-11) therapy for advanced gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Humans; Irinotecan; Mitomycin; Stomach Neoplasms; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
Rationale for mitomycin and irinotecan use in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mitomycin; Women's Health | 2003 |
[The update on pancreatic cancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Infusions, Intra-Arterial; Irinotecan; Male; Mitomycin; Multicenter Studies as Topic; Pancreatic Neoplasms; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2003 |
Palliative cytostatic treatment of cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Mitomycin; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Survival Analysis; Uterine Cervical Neoplasms; Vindesine | 2003 |
Chemotherapy-induced lung disease.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bleomycin; Busulfan; Camptothecin; Cyclophosphamide; Humans; Iatrogenic Disease; Interferons; Irinotecan; Lung Diseases; Methotrexate; Mitomycin; Nitrosamines; Respiratory Function Tests; Tretinoin | 2004 |
[Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Irinotecan; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
[CPT-11 combined chemotherapy for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Regional chemotherapy for liver-limited metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Mitomycin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2008 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Hemolytic-Uremic Syndrome; Humans; Irinotecan; Mitomycin; Prospective Studies; Purpura, Thrombotic Thrombocytopenic | 2010 |
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Mutation; Organoplatinum Compounds; Oxaloacetates; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Vascular Endothelial Growth Factor A | 2012 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
35 trial(s) available for mitomycin and camptothecin
| Article | Year |
|---|---|
[Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C].
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Remission Induction; Survival Rate | 1996 |
A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Survival Rate; Time Factors | 1998 |
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2000 |
Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Topics: Actuarial Analysis; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Salvage Therapy; Survival Analysis; Treatment Failure; Treatment Outcome | 2001 |
Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Staging | 2001 |
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Survival Rate; Thrombocytopenia | 2001 |
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Treatment Outcome | 2002 |
Mitomycin as a modulator of irinotecan anticancer activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Mitomycin; Neoplasm Staging; Neoplasms; Patient Selection; Prognosis; Survival Analysis; Treatment Outcome | 2002 |
IPM chemotherapy in cytokine refractory renal cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Kidney Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Survival; Treatment Outcome | 2003 |
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin | 2003 |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Odds Ratio; Probability; Risk Assessment; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2003 |
[Prospective randomized study of HMVP, MVP, and HVP regimens in treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Prospective Studies; Vindesine | 2004 |
Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prospective Studies; Uterine Cervical Neoplasms | 2004 |
Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Pancreatic Neoplasms; Salvage Therapy; Taxoids; Treatment Outcome | 2004 |
Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Pilot Projects | 2004 |
Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Prospective Studies | 2005 |
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Italy; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neutropenia; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Uterine Cervical Neoplasms | 2005 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Japan; Mitomycin; Ovarian Neoplasms; Pilot Projects; Salvage Therapy; Uterine Cervical Neoplasms | 2006 |
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Quality of Life; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neutropenia; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Gene Expression; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mitomycin; NAD(P)H Dehydrogenase (Quinone); Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2008 |
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasms; Pyrazoles; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Mesothelioma; Middle Aged; Mitomycin; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate | 2009 |
[Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2009 |
Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Radiotherapy, Adjuvant; Vindesine | 2010 |
Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2011 |
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Japan; Male; Methotrexate; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2011 |
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2011 |
A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2013 |
Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Deoxycytidine; Epidemiologic Methods; Female; Gelatin Sponge, Absorbable; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Quinazolines; Thiophenes; Treatment Outcome | 2013 |
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Fluorouracil; Humans; Hyperthermic Intraperitoneal Chemotherapy; Leucovorin; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Perioperative Period; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors | 2021 |
112 other study(ies) available for mitomycin and camptothecin
| Article | Year |
|---|---|
Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Boswellia; Cell Line, Tumor; DNA Fragmentation; Growth Inhibitors; Humans; Triterpenes | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
2-Anilinonicotinyl linked 2-aminobenzothiazoles and [1,2,4]triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates as potential mitochondrial apoptotic inducers.
Topics: Aniline Compounds; Animals; Apoptosis; Benzothiadiazines; Caspases; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Screening Assays, Antitumor; Growth Inhibitors; Haplorhini; HL-60 Cells; Humans; Mitochondria; Nicotine | 2011 |
Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Flow Cytometry; HL-60 Cells; Humans; Models, Chemical; NF-kappa B; Phosphorylation; STAT Transcription Factors; Triterpenes | 2012 |
Bakuchiol derivatives as novel and potent cytotoxic agents: a report.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Humans; Neoplasms; Phenols; Psoralea | 2012 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Synthesis, structure activity relationship and mode of action of 3-substitutedphenyl-1-(2,2,8,8-tetramethyl-3,4,9,10-tetrahydro-2H,8H-pyrano[2,3-f]chromen-6-yl)-propenones as novel anticancer agents in human leukaemia HL-60 cells.
Topics: Antineoplastic Agents; Benzopyrans; Caco-2 Cells; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chalcones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; MCF-7 Cells; Molecular Structure; Structure-Activity Relationship | 2013 |
Synthesis and anticancer activity of novel spiro-isoxazoline and spiro-isoxazolidine derivatives of α-santonin.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flow Cytometry; G1 Phase; Humans; Inhibitory Concentration 50; Isoxazoles; MCF-7 Cells; Models, Chemical; Molecular Conformation; Molecular Structure; Santonin; Stereoisomerism; Transcription Factor RelA | 2013 |
Synthesis of 3-O-propargylated betulinic acid and its 1,2,3-triazoles as potential apoptotic agents.
Topics: Apoptosis; Betulinic Acid; Cell Line, Tumor; Cell Movement; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Electrophoresis, Agar Gel; HL-60 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Membrane Potential, Mitochondrial; Models, Chemical; Molecular Structure; Pentacyclic Triterpenes; Structure-Activity Relationship; Triazoles; Triterpenes | 2013 |
β-Ionone derived chalcones as potent antiproliferative agents.
Topics: Animals; Apoptosis; Cell Cycle; Cell Proliferation; Chalcones; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; Hep G2 Cells; Humans; MCF-7 Cells; Molecular Structure; Norisoprenoids; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
Design and synthesis of novel 1,2,3-triazole derivatives of coronopilin as anti-cancer compounds.
Topics: Antineoplastic Agents; Azulenes; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; MCF-7 Cells; Molecular Structure; Sesquiterpenes; Structure-Activity Relationship; Triazoles | 2014 |
Synthesis and evaluation of 3-salicyloylpyridine derivatives as cytotoxic mitochondrial apoptosis inducers.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; MCF-7 Cells; Membrane Potential, Mitochondrial; Mitochondria; Models, Molecular; Molecular Structure; Phenols; Pyridines; Reactive Oxygen Species; Structure-Activity Relationship | 2014 |
β-Ionone derived apoptosis inducing endoperoxides; Discovery of potent leads for anticancer agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; DNA; Drug Design; Humans; Intracellular Space; L-Lactate Dehydrogenase; Membrane Potential, Mitochondrial; Norisoprenoids; Peroxides; Reactive Oxygen Species | 2014 |
Synergistic induction of erythroid differentiation of mouse erythroleukemia (MEL) cells by inhibitors of topoisomerases and protein tyrosine kinases.
Topics: Acetamides; Amsacrine; Animals; Blotting, Western; Camptothecin; Cell Differentiation; Cinnamates; Dimethyl Sulfoxide; Hemoglobins; Leukemia, Erythroblastic, Acute; Mice; Mitomycin; Protein-Tyrosine Kinases; Sulfides; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vanadates | 1992 |
Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
Topics: Camptothecin; Cell Death; Cisplatin; DNA Damage; DNA, Neoplasm; Drug Synergism; Epirubicin; Etoposide; Female; Humans; Mitomycin; Ovarian Neoplasms; Recombinant Proteins; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1992 |
[Combination therapy of CPT-11, a camptothecin derivative, with various antitumor drugs against L 1210 leukemia].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Female; Irinotecan; Leukemia L1210; Methotrexate; Mice; Mitomycin; Mitomycins; Thioinosine | 1991 |
Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents.
Topics: Animals; Camptothecin; Cell Line; Cell Survival; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Cross-Linking Reagents; DNA Damage; Female; Guinea Pigs; Mechlorethamine; Melphalan; Mitomycin; Mutation; Radiation Tolerance; Ultraviolet Rays | 1991 |
Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Line; Cell Survival; Chromosome Aberrations; Cricetinae; Drug Resistance; Ellipticines; Etoposide; Mitomycin; Mitomycins; Sister Chromatid Exchange; Topoisomerase II Inhibitors | 1988 |
[Combination chemotherapy of BOF-A2, a new 5-FU derivative, with various anticancer agents against human cancer xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Interferon-alpha; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Neoplasm Transplantation; Transplantation, Heterologous | 1994 |
Fanconi anemia cells have a normal gene structure for topoisomerase I.
Topics: Base Sequence; Camptothecin; Cell Line; Cell Survival; Cell Transformation, Viral; Cells, Cultured; DNA; DNA Mutational Analysis; DNA Primers; DNA Topoisomerases, Type I; Fanconi Anemia; Humans; Mitomycin; Molecular Sequence Data; Polymerase Chain Reaction | 1994 |
Induction of protein-DNA complexes in HeLa S3 cells by KW-2149, a new derivative of mitomycin C.
Topics: Antineoplastic Agents; Camptothecin; DNA, Neoplasm; Dose-Response Relationship, Drug; HeLa Cells; Humans; Kinetics; Mercaptoethanol; Mitomycin; Mitomycins; Molecular Structure; Neoplasm Proteins; Protein Binding; Structure-Activity Relationship; Thymidine | 1993 |
Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Cell Death; DNA Damage; DNA, Neoplasm; Doxorubicin; Humans; Irinotecan; Lung Neoplasms; Mice; Mitomycin; Molecular Sequence Data; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transfection; Tumor Cells, Cultured | 1993 |
Activation of protein kinase Cdelta in human myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine.
Topics: Amino Acid Sequence; Apoptosis; Camptothecin; Cytarabine; DNA Damage; Endopeptidases; Enzyme Activation; Genes, jun; Humans; Intracellular Signaling Peptides and Proteins; Isoenzymes; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Membrane Proteins; Mitomycin; Molecular Sequence Data; Myelin Basic Protein; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Proteins; Neoplastic Stem Cells; Nucleosomes; Phosphorylation; Protein Kinase C; Protein Kinase C-delta; Protein Processing, Post-Translational; Proteins; Signal Transduction; Substrate Specificity; Tumor Cells, Cultured | 1996 |
[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1996 |
Sister-chromatid exchanges (SCE) induction by inhibitors of DNA topoisomerases in cultured human lymphocytes.
Topics: Amsacrine; Camptothecin; Cells, Cultured; Enzyme Inhibitors; Etoposide; Humans; Lymphocytes; Mitomycin; Nalidixic Acid; Sister Chromatid Exchange; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1996 |
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Etoposide; Genes, MDR; Humans; Irinotecan; Mitomycin; Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Verapamil; Vincristine | 1996 |
[Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
Topics: Antineoplastic Agents, Alkylating; Bleomycin; Camptothecin; Cell Division; Cisplatin; Cross-Linking Reagents; Dioxoles; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Humans; Isoquinolines; Male; Mitomycin; Models, Molecular; Molecular Structure; Neoplasm Proteins; Paclitaxel; Phthalimides; Structure-Activity Relationship; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 1999 |
Immortalization and characterization of Nijmegen Breakage syndrome fibroblasts.
Topics: Abnormalities, Multiple; Antineoplastic Agents; Bleomycin; Camptothecin; Cell Line; Cell Line, Transformed; Cell Survival; Cell Transformation, Viral; Child, Preschool; Chromosome Breakage; DNA; DNA Damage; DNA Repair; Etoposide; Fibroblasts; HeLa Cells; Humans; Mitomycin; Mutation; Syndrome; X-Rays | 1999 |
The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.
Topics: Animals; Base Sequence; Binding Sites; Breast Neoplasms; Camptothecin; Catalysis; Cell Line; DNA; DNA Topoisomerases, Type I; Female; Kinetics; Mitomycin; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Recombinant Proteins; Sequence Deletion; Transcription Factors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
The isolation and genetic analysis of V79-derived etoposide sensitive Chinese hamster cell mutants: two new complementation groups of etoposide sensitive mutants.
Topics: Animals; Camptothecin; Cell Separation; CHO Cells; Cricetinae; Doxorubicin; Etoposide; Genetic Complementation Test; Mitomycin; Mutation; Nucleic Acid Hybridization; Streptonigrin; Topoisomerase II Inhibitors | 1999 |
In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Coloring Agents; Drug Synergism; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Rectal Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Tumor Cells, Cultured | 2000 |
In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Etoposide; Fluorouracil; Gemcitabine; Humans; Mitomycin; Models, Chemical; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Isolation of camptothecin-sensitive chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Bleomycin; Camptothecin; Cell Cycle; Cell Cycle Proteins; Cell Line; Cricetinae; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Enzyme Inhibitors; Etoposide; Gamma Rays; Genes, Dominant; Genetic Complementation Test; Mitomycin; Mutation; Nucleic Acid Synthesis Inhibitors; Phenotype; Protein Serine-Threonine Kinases; Streptonigrin; Tumor Suppressor Proteins | 2000 |
Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Mitomycin; Ovarian Neoplasms; Peritoneal Neoplasms | 2000 |
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Cytokines; Epithelial Cell Adhesion Molecule; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; HT29 Cells; Humans; Interferons; Interleukins; Irinotecan; Lewis Blood Group Antigens; Macrophage Colony-Stimulating Factor; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Up-Regulation | 2001 |
Anticancer drugs as inducers of thermotolerance in yeast.
Topics: Antineoplastic Agents; Bleomycin; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Fluorouracil; Hot Temperature; Irinotecan; Methotrexate; Mitomycin; Saccharomyces | 2000 |
Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death in murine thymoma EL-4 cells.
Topics: Animals; Apoptosis; Camptothecin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase Inhibitors; Cell Membrane; Cycloheximide; Down-Regulation; Doxorubicin; Etoposide; Fas Ligand Protein; fas Receptor; Gene Expression; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Mitomycin; Protein Synthesis Inhibitors; Thymoma; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Up-Regulation | 2002 |
[Apoptosis as a measure of chemosensitivity to anti-cancer drugs in gynecological cancer].
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Female; Humans; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Neoplasms | 2002 |
Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Female; Humans; Methotrexate; Mitomycin; RNA, Messenger; Tumor Cells, Cultured | 2002 |
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Coloring Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione; Humans; Inhibitory Concentration 50; Irinotecan; Mitochondrial Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
Chromosomal instability in B-lymphoblasotoid cell lines from Werner and Bloom syndrome patients.
Topics: 4-Nitroquinoline-1-oxide; B-Lymphocytes; Bloom Syndrome; Camptothecin; Carcinogens; Case-Control Studies; Cell Division; Cell Line; Chromosome Aberrations; Etoposide; Herpesvirus 4, Human; Humans; Karyotyping; Metaphase; Micronuclei, Chromosome-Defective; Mitomycin; Sister Chromatid Exchange; Werner Syndrome | 2002 |
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Esophageal Neoplasms; Female; Gastrointestinal Diseases; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Treatment Outcome | 2002 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Mitomycin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Sampling Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Schizosaccharomyces pombe checkpoint response to DNA interstrand cross-links.
Topics: Camptothecin; Cell Survival; Checkpoint Kinase 2; Cisplatin; Cross-Linking Reagents; DNA; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Enzyme Inhibitors; G2 Phase; Hydroxyurea; Mitomycin; Nucleic Acid Synthesis Inhibitors; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Radiation-Sensitizing Agents; Recombination, Genetic; S Phase; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Temperature; Time Factors | 2003 |
Acquisition of drug resistance by constitutive suppression of NF-kappaB in ras-transformed NIH3T3 mouse fibroblasts.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Cell Line, Transformed; Cell Nucleus; Cell Survival; Coloring Agents; DNA; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Flow Cytometry; Mice; Mitomycin; NF-kappa B; NIH 3T3 Cells; Peplomycin; Tetrazolium Salts; Thiazoles; Transfection | 2003 |
[A case of unresectable liver metastases from rectosigmoid colon cancer with survival for over 3 years after multidisciplinary treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Rectal Neoplasms; Sigmoid Neoplasms | 2003 |
A tumour-derived mutant allele of XRCC2 preferentially suppresses homologous recombination at DNA replication forks.
Topics: Base Pair Mismatch; Camptothecin; DNA; DNA Repair; DNA Replication; DNA-Binding Proteins; Female; Genes, Reporter; Humans; Leiomyosarcoma; Mitomycin; Mutation; Recombination, Genetic; Sarcoma; Thymidine; Tumor Cells, Cultured; Uterine Neoplasms | 2004 |
Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin.
Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Body Weight; Camptothecin; Cell Line, Tumor; Cisplatin; Coloring Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Heme Oxygenase (Decyclizing); Humans; Hydrogen Peroxide; Male; Metalloporphyrins; Mice; Mitomycin; Neoplasms; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxygen; Polyethylene Glycols; Proline; Reactive Oxygen Species; Tetrazolium Salts; Thiazoles | 2004 |
Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failure.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Mitomycin; Oxonic Acid; Pyridines; Radiography; Stomach Neoplasms; Tegafur; Treatment Failure | 2004 |
Cell cycle-dependent regulation of a human DNA helicase that localizes in DNA damage foci.
Topics: Amino Acid Motifs; Amino Acid Sequence; Camptothecin; CDC2-CDC28 Kinases; Cell Cycle; Cyclin-Dependent Kinase 2; DNA; DNA Damage; DNA Helicases; DNA Mutational Analysis; G1 Phase; Humans; Intracellular Space; Mitomycin; Molecular Sequence Data; Phosphorylation; Serine | 2004 |
Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Camptothecin; Carrier Proteins; Cell Line; Cisplatin; DNA Repair; Drug Screening Assays, Antitumor; Etoposide; Furocoumarins; Humans; Inhibitory Concentration 50; Melphalan; Mitomycin; MutL Protein Homolog 1; Neoplasm Proteins; Nitrosourea Compounds; Nuclear Proteins | 2004 |
[Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Data Interpretation, Statistical; Fluorouracil; Gastrointestinal Neoplasms; Irinotecan; Male; Mitomycin; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Rats; Time Factors; Tumor Cells, Cultured | 2004 |
[Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Pyrimidines; Retrospective Studies; Survival Rate | 2004 |
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Logistic Models; Male; Mesothelioma; Middle Aged; Mitomycin; Models, Theoretical; Organoplatinum Compounds; Oxaliplatin; Pleural Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2005 |
DNA lesion-specific co-localization of the Mre11/Rad50/Nbs1 (MRN) complex and replication protein A (RPA) to repair foci.
Topics: Acid Anhydride Hydrolases; Blotting, Western; Camptothecin; Cations; Cell Cycle Proteins; Cell Nucleus; Comet Assay; DNA; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; DNA, Single-Stranded; Etoposide; HeLa Cells; Humans; Hydroxyurea; Macromolecular Substances; Microscopy, Fluorescence; Mitomycin; Models, Biological; MRE11 Homologue Protein; Multiprotein Complexes; Nuclear Proteins; Phosphorylation; Protein Binding; Replication Protein A; Time Factors | 2005 |
Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cisplatin; Cytokines; Drug Resistance, Neoplasm; Humans; Irinotecan; Kidney Neoplasms; Mitomycin; Neoplasm Metastasis; Prognosis | 2005 |
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cluster Analysis; Computational Biology; Databases as Topic; DNA, Complementary; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mitomycin; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phylogeny; Sensitivity and Specificity; Tissue Distribution; Transfection; Vinblastine; Vinorelbine | 2005 |
[Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationships to expressions of P-glycoprotein and glutathione S transferase-pi].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Nucleus; Cisplatin; Cytoplasm; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Male; Middle Aged; Mitomycin; Stomach Neoplasms; Tumor Cells, Cultured | 2005 |
[Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Mitomycin; Peritoneal Neoplasms; Survivors | 2005 |
In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Leucovorin; Male; Middle Aged; Mitomycin; Taxoids | 2005 |
Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Disease Progression; Hepatic Artery; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Mitomycin; Rectal Neoplasms; Remission Induction; Starch; Stomach Neoplasms; Topoisomerase I Inhibitors | 2006 |
[A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Male; Mitomycin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2006 |
Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Topics: Antigens, CD20; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; CD40 Antigens; Cell Survival; Clone Cells; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Fluorouracil; Humans; Integrin alpha1; Integrin alpha6; Irinotecan; Mitomycin; Uterine Cervical Neoplasms; X-Rays | 2006 |
Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Cytokines; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; HT29 Cells; Humans; Interferons; Ligands; Mitomycin; Orotate Phosphoribosyltransferase; Paclitaxel; RNA, Messenger; Thymidine Phosphorylase; Thymidylate Synthase | 2006 |
[Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemoth
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Mitomycin; Rectal Neoplasms; Starch | 2006 |
Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Male; Mesothelioma; Middle Aged; Mitomycin; Pleural Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2007 |
5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate | 2006 |
A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Apraxias; Ataxia; Blotting, Western; Camptothecin; Cells, Cultured; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; Etoposide; Female; Flow Cytometry; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Methylnitronitrosoguanidine; Mitomycin; Oxidative Stress; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Radiation, Ionizing; Reactive Nitrogen Species | 2007 |
Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.
Topics: Camptothecin; Cisplatin; Cytotoxins; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Melphalan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Peritoneal Neoplasms; Tumor Cells, Cultured | 2008 |
Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; BCG Vaccine; Camptothecin; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cross-Linking Reagents; DNA Fragmentation; DNA, Neoplasm; Humans; Mitomycin; Urinary Bladder Neoplasms | 2007 |
"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drainage; Female; Fluorouracil; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Seeding; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Care; Retrospective Studies; Treatment Outcome | 2009 |
Fanconi anemia proteins stabilize replication forks.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Aphidicolin; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle Proteins; Cell Nucleus; Cell-Free System; Chromatin; DNA Damage; DNA Repair; DNA Replication; Enzyme Inhibitors; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Fanconi Anemia Complementation Group L Protein; Mitomycin; Phosphorylation; Protein Serine-Threonine Kinases; Xenopus laevis; Xenopus Proteins | 2008 |
Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Palliative Care; Prospective Studies; Survival Rate; Tomography, Spiral Computed | 2009 |
In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Organoplatinum Compounds; Pyridines; Regression Analysis; Tumor Cells, Cultured | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Mitomycin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur; Xenograft Model Antitumor Assays | 2009 |
Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Prospective Studies | 2009 |
Characterization of two novel SETX mutations in AOA2 patients reveals aspects of the pathophysiological role of senataxin.
Topics: Adult; Apoptosis; Apraxia, Ideomotor; Ataxia; Camptothecin; DNA Damage; DNA Helicases; Eye Diseases; Female; Homozygote; Humans; Hydrogen Peroxide; Male; Middle Aged; Mitomycin; Multifunctional Enzymes; Mutation; Pedigree; RNA Helicases | 2010 |
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Irinotecan; Leucovorin; Mice; Mice, Nude; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
Topics: Adult; Aged; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Fluorouracil; Humans; Imaging, Three-Dimensional; Liver Neoplasms; Male; Middle Aged; Mitomycin; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome | 2009 |
The cellular phenotype of Roberts syndrome fibroblasts as revealed by ectopic expression of ESCO2.
Topics: Acetyltransferases; Camptothecin; Cell Cycle Proteins; Chromosomal Proteins, Non-Histone; Chromosome Aberrations; Chromosome Segregation; Cohesins; Congenital Abnormalities; DNA Damage; Etoposide; Fibroblasts; Growth Disorders; Humans; Infant; Male; Mitomycin; Nucleic Acid Synthesis Inhibitors; Sister Chromatid Exchange; Syndrome | 2009 |
[Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel].
Topics: Air Pollutants, Occupational; Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Decontamination; Doxorubicin; Drug Compounding; Electrosurgery; Hot Temperature; Humans; Irinotecan; Mitomycin; Occupational Exposure; Operating Rooms; Organoplatinum Compounds; Peritoneal Neoplasms; Protective Clothing; Pyridines; Smoke; Ventilation | 2009 |
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Capecitabine; Caspases; Cell Cycle Proteins; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; DNA Damage; Doxorubicin; Flow Cytometry; Fluorouracil; Glutamates; Guanine; Histones; Humans; Immunoenzyme Techniques; Mitomycin; Nuclear Proteins; Pemetrexed; Phosphorylation; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Rats; Rats, Inbred F344; Rats, Nude; Xenograft Model Antitumor Assays | 2010 |
Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents.
Topics: 5' Untranslated Regions; Apoptosis; Camptothecin; Cell Hypoxia; Cell Line; Cyclin-Dependent Kinases; DNA Damage; Etoposide; Eukaryotic Initiation Factor-2; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitomycin; Phosphorylation; Protein Biosynthesis; Protein Processing, Post-Translational; Signal Transduction; Transcription, Genetic; Tumor Suppressor Protein p53 | 2010 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Glucuronosyltransferase; Health Surveys; Humans; Irinotecan; Mitomycin; Neutropenia; Organoplatinum Compounds; Pyridines; Risk Factors; State Medicine; United Kingdom | 2010 |
Role of senataxin in DNA damage and telomeric stability.
Topics: Camptothecin; Cell Line, Tumor; Chromosome Aberrations; DNA Damage; DNA Helicases; DNA Repair; Humans; Hydrogen Peroxide; In Situ Hybridization, Fluorescence; Lymphocytes; Mitomycin; Multifunctional Enzymes; RNA Helicases; Spinocerebellar Ataxias; Spinocerebellar Degenerations; Telomere; X-Rays | 2011 |
SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype.
Topics: Alleles; Camptothecin; Child; Cross-Linking Reagents; DNA Repair; Dose-Response Relationship, Drug; Fanconi Anemia; Heat-Shock Proteins; HSC70 Heat-Shock Proteins; Humans; Immunoprecipitation; Male; Mitomycin; Mutation; Phenotype; Recombinases | 2011 |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
p21 promotes error-free replication-coupled DNA double-strand break repair.
Topics: Animals; BRCA2 Protein; Camptothecin; Chromosomal Instability; Cross-Linking Reagents; Cyclin-Dependent Kinase Inhibitor p21; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA Repair; DNA Repair Enzymes; DNA Replication; DNA-Binding Proteins; Etoposide; G1 Phase Cell Cycle Checkpoints; HCT116 Cells; HeLa Cells; Humans; Mice; Mitomycin; MRE11 Homologue Protein; Phosphorylation; Recombinational DNA Repair; Topoisomerase Inhibitors | 2012 |
Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Retrospective Studies | 2013 |
Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4.
Topics: Camptothecin; Cell Line; Cross-Linking Reagents; DNA; DNA Mutational Analysis; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Endodeoxyribonucleases; Endonucleases; Fanconi Anemia; Humans; Mitomycin; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Interaction Mapping; Protein Structure, Tertiary; Recombinant Fusion Proteins; Recombinases; Topoisomerase I Inhibitors | 2013 |
Preclinical antitumor activity of a nanoparticulate SN38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Female; HCT116 Cells; Humans; Irinotecan; Mice; Mitomycin; Nanoparticles; Neoplasms; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
Comparison of the effects of mitomycin C and 10-hydroxycamptothecin on an experimental intraarticular adhesion model in rabbits.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cartilage, Articular; Cell Adhesion; Cell Count; Fibroblasts; Hydroxyproline; Knee Joint; Male; Mitomycin; Protective Agents; Rabbits | 2013 |
A high-throughput yeast assay identifies synergistic drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Humans; Irinotecan; Mitomycin; Neoplasms; Two-Hybrid System Techniques | 2013 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2013 |
The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cells, Cultured; Cisplatin; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gastric Mucosa; Glutathione S-Transferase pi; Humans; In Vitro Techniques; Mitomycin; Stomach; Stomach Neoplasms | 2013 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Irinotecan; Male; Mesothelioma; Middle Aged; Mitomycin; Neoplasms, Multiple Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Pseudomyxoma Peritonei; Quality of Life; Stomach Neoplasms; Treatment Outcome | 2014 |
[A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinosarcoma; Combined Modality Therapy; Fatal Outcome; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Stomach Neoplasms | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusion; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Gallbladder Neoplasms; Humans; Hyperthermia, Induced; Intraoperative Care; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Stomach Neoplasms; Survival Rate; Tertiary Care Centers | 2014 |
An RNA synthesis inhibition assay for detecting toxic substances using click chemistry.
Topics: Animals; Camptothecin; Cell Differentiation; Cisplatin; Click Chemistry; Depression, Chemical; DNA Damage; Hazardous Substances; HeLa Cells; Humans; Mitomycin; Mutagenicity Tests; Nitroso Compounds; PC12 Cells; Rats; RNA; Titanium; Transcription, Genetic | 2014 |
The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Calreticulin; Camptothecin; Carcinoma, Lewis Lung; CD3 Complex; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunomodulation; Lymphocyte Count; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mitomycin; Mitoxantrone; Neoplasm Transplantation; Neoplasms, Experimental; Protein Transport; T-Lymphocytes; Tumor Microenvironment | 2015 |
Differential contribution of the Fanconi anemia-related proteins to repair of several types of DNA damage in cultured silkworm cells.
Topics: Animals; Bombyx; Camptothecin; Cells, Cultured; DNA Damage; DNA Helicases; DNA Repair; Fanconi Anemia Complementation Group D2 Protein; Histones; Homologous Recombination; Humans; Hydroxyurea; Mitomycin; Phosphorylation; Ubiquitination | 2014 |
Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Proliferation; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Pseudomyxoma Peritonei; Tumor Cells, Cultured; Young Adult | 2015 |
FANCJ suppresses microsatellite instability and lymphomagenesis independent of the Fanconi anemia pathway.
Topics: Animals; Antineoplastic Agents; Basic-Leucine Zipper Transcription Factors; Camptothecin; Cell Line; Cells, Cultured; DNA Damage; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Fanconi Anemia Complementation Group Proteins; Female; Fibroblasts; Genetic Predisposition to Disease; Humans; Lymphoma; Male; Mice, Knockout; Microsatellite Instability; Mitomycin; Neoplasms, Glandular and Epithelial; RNA Helicases; Ultraviolet Rays | 2015 |
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Male; Middle Aged; Mitomycin; Retrospective Studies; Survival Rate | 2016 |
Digital Glissonectomy: A Safe Perihepatic Peritonectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Pseudomyxoma Peritonei; Young Adult | 2016 |
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Piperazines; Retreatment; Treatment Outcome | 2017 |
Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Ethiodized Oil; Female; Gemcitabine; Humans; Hyperthermia, Induced; Irinotecan; Laser Therapy; Liver Neoplasms; Male; Microwaves; Middle Aged; Mitomycin; Neoadjuvant Therapy; Palliative Care; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Ginsenoside Rg1 impairs homologous recombination repair by targeting CtBP-interacting protein and sensitizes hepatoblastoma cells to DNA damage.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carrier Proteins; Cell Growth Processes; Cell Line, Tumor; DNA Damage; Drug Synergism; Endodeoxyribonucleases; Ginsenosides; Hep G2 Cells; Hepatoblastoma; Humans; Hydroxyurea; Liver Neoplasms; Male; Mice; Mice, Nude; Mitomycin; Nuclear Proteins; Phthalazines; Piperazines; Random Allocation; Recombinational DNA Repair; Xenograft Model Antitumor Assays | 2018 |
Chemical modulation of apoptosis in molluscan cell cultures.
Topics: Animals; Apoptosis; Camptothecin; Cell Survival; Cells, Cultured; Cold-Shock Response; Humans; Mice; Mitomycin; Mytilus; Staurosporine | 2019 |
Succinylation at a key residue of FEN1 is involved in the DNA damage response to maintain genome stability.
Topics: Camptothecin; Cell Cycle Proteins; DNA Damage; DNA Repair; DNA Replication; Exonucleases; Flap Endonucleases; Genome, Human; Genomic Instability; Humans; Hydroxyurea; Mitomycin; Multiprotein Complexes; Proliferating Cell Nuclear Antigen; Protein Processing, Post-Translational; Succinic Acid; SUMO-1 Protein; Sumoylation; Ultraviolet Rays | 2020 |